Powered by MOMENTUM MEDIA

Website Notifications

Get notifications in real-time for staying up to date with content that matters to you.

JP2060 Phase 3 contender sets sights on human health research

monash leidos mou

Leidos Australia has signed a memorandum of understanding (MoU) with Monash University to collaborate on research and development at the Monash Institute of Medical Engineering (MIME).

Leidos Australia has signed a memorandum of understanding (MoU) with Monash University to collaborate on research and development at the Monash Institute of Medical Engineering (MIME).

MIME fosters and co-ordinates translational medtech research across Monash University faculties, partner hospitals and collaborating medical research institutions. The clinician-led research programs focus on major clinical and health system needs, and integrate expertise from across engineering, information technology, science, biomedical and clinical research to develop new devices, diagnostics, therapeutics, delivery systems and clinical tools.

Advertisement
Advertisement

The MoU, signed by the director of MIME, Professor Jeffrey Rosenfeld AM, OBE, and Leidos Australia technical director Dan Brewer, will focus on the development of innovative technologies and solutions to address human health problems.

"It will foster the development of new technology and IT solutions for human health problems," said Professor Rosenfeld.

"University-industry collaboration is an important goal to create new opportunities for Australian innovation to reach the marketplace."

Brewer added, “Health is a key area for Leidos globally and as we continue to grow domestically, we will be looking to further develop our range of capabilities in this area."

The MoU will also see Leidos Australia and the MIME collaborate on future R&D with the initial contribution including the funding of a PhD research student.

PROMOTED CONTENT

Leidos is one of the primes tendering for Defence's Deployable Health Capability (JP2060 Phase 3), which aims to introduce an entire system (mission system), inclusive of all medical and dental equipment (a turn key solution) and designed to operate as an integrated capability.

The company also signed another MoU with the University of New South Wales to collaborate on research into the development of force protection and biological security for the Australian Defence Force.

JP2060 Phase 3 contender sets sights on human health research
Monash-Leidos-MoU.jpg
lawyersweekly logo

The inaugural Defence Connect AIC Summit will place you with key decision-makers and stakeholders within the defence industry to discuss the government’s intention to improve AIC and increase the nation’s sovereign production, defence capability and resilience. Don’t miss your chance to be part of this event, register for free today to attend the live stream on 22 October. Register your interest to attend, visit: www.defenceconnect.com.au/aic-summit

more from defence connect

EOS tests T2000 turret at NSW range
07:00
EOS tests T2000 turret at NSW range
The company has put its turret to the test during a live-fire exercise at a private range. ...
Sep 17 2021
FTS Group continues growth in ANZ rebranded as Atturra
FTS Group, an Australian technology consulting and services business, has announced its rebrand to Atturra. ...
Sep 17 2021
Babcock Australasia tips hat to AUKUS deal
The global defence company had lauded Australia’s new nuclear submarine arrangement with its major allies. ...